APPLICATION OF HIGH RESOLUTION MELTING (HRM) ANALYSIS IN DETECTION OF PDGFRA GENE MUTATIONS AMONG CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE

NUR SABRINA BINTI ABD RASHID

UNIVERSITI SAINS MALAYSIA

2020
APPLICATION OF HIGH RESOLUTION MELTING (HRM) ANALYSIS IN DETECTION OF PDGFRA GENE MUTATIONS AMONG CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE

by

NUR SABRINA BINTI ABD RASHID

Thesis submitted in fulfilment of the requirements for the Degree of Master of Science

March 2020
ACKNOWLEDGEMENTS

In the name of Allah, the Most Generous and the Most Merciful. All praises are devoted to Allah for His guidance and peace that give me the ingredients of success.

First of all, I would like to thank my supervisor, Dr. Nazihah Mohd Yunus from Human Genome Centre Department, for her support, excellent guidance and supervision throughout this study. Her guidance and encouragement are greatly appreciated. I also like to convey my gratitude to my co-supervisors, Associate Professor Dr. Sarina Sulong and Associate Professor Dr. Azlan Husin for their encouragement, kind supervision and assistance during this study. I would like to extend my gratitude to all the lecturers, staff especially to En Mohamad Ros Sidek and my colleagues from Human Genome Centre for sharing their knowledge and experience.

The financial assistance from Ministry of Higher Education through University Short Term Grant 304/PPSP/61313124 is gratefully acknowledged. Without this grant, it would have been impossible to carry this study. I also owe my sincere thanks to Universiti Sains Malaysia for awarding me the Graduated Research Assistant (GRA) for a year during my study.

Finally, I wish to acknowledge the greatest support, love and encouragement from my beloved husband, Mohd Zaki Hussin, my dear son Muhammad Hayyan Adzka and my parents Abd Rashid Marjo and Rodiah Samsuni. Not forgotten, my siblings, all my in laws and all people who were involved directly or indirectly in my MSc for their love, patience, support and their faith in me.
LIST OF CONTENTS

ACKNOWLEDGEMENTS ii
LIST OF CONTENTS iii
LIST OF SYMBOL AND APPENDICES vii
LIST OF TABLES ix
LIST OF FIGURES xi
LIST OF APPENDICES xiii
ABSTRAK xiv
ABSTRACT xvi

CHAPTER 1 LITERATURE REVIEW

1.1 Study overview 1
1.2 Chronic Myeloid Leukemia and clinical phases 7
1.3 Diagnosis of CML 8
1.4 Treatment and management 9
1.5 Imatinib mesylate 9
   1.5.1 Mechanism of action 12
1.6 IM resistance 14
   1.6.1 BCR-ABL dependent 17
   1.6.2 BCR-ABL independent 18
1.7 Tyrosine kinase 21
   1.7.1 Platelet-derived growth factor receptor alpha (PDGFRA) 22
   1.7.2 PDGFRA and IM resistance 24
1.8 High resolution melting (HRM) analysis 25
1.9 Rationale of study 28
1.10 Study objectives 29
   1.10.1 General objective 29
   1.10.2 Specific objectives 29
# CHAPTER 2  METHODOLOGY

2.1 Study design and ethical approval  
2.1.1 Sample size determination  

2.2 Sample collection and patients recruitment  
2.2.1 Inclusion criteria  
2.2.2 Exclusion criteria  

2.3 Genomic DNA extraction  
2.3.1 DNA extraction procedure  

2.4 DNA quantification and qualification  

2.5 Mutation screening using High Resolution Melt (HRM) analysis  
2.5.1 Principle of HRM analysis  
2.5.2 Selection of exons for HRM analysis  
2.5.3 Primer design  
2.5.4 HRM analysis  
2.5.4 (a) Assay optimization  
2.5.4 (b) Preparation of master mix  
2.5.4 (c) Sample loading and HRM analysis set-up  

2.6 Polymerase Chain Reaction (PCR)  
2.6.1 PCR principle  
2.6.2 Primers selection  
2.6.3 Optimization of PCR reaction  
2.6.4 PCR master mix preparation  
2.6.5 PCR program set up  

2.7 Agarose Gel Electrophoresis  
2.7.1 Reagent for Agarose gel electrophoresis  
2.7.2 Tris-Borate EDTA (TBE) buffer preparation  
2.7.3 Preparation of agarose gel  
2.7.4 Agarose Gel electrophoresis set-up  

2.8 PCR purification  

2.9 DNA Sequencing  

2.10 Statistical Analysis
CHAPTER 3     RESULTS

3.1 Sociodemographic and clinical phases of CML patients ........................................... 65
3.2 Genomic DNA qualification ......................................................................................... 67
3.3 Mutational analysis using High Resolution Melting (HRM) ......................................... 69
   3.3.1 Amplification graph ............................................................................................... 69
   3.3.2 HRM analysis for exon 10 PDGFRA .................................................................... 71
   3.3.3 HRM analysis for exon 12 PDGFRA .................................................................... 73
   3.3.4 HRM analysis for exon 14 PDGFRA .................................................................... 75
   3.3.5 HRM analysis for exon 18 PDGFRA .................................................................... 77
3.4 PCR amplification of exons 10, 12, 14 and 18 of the PDGFRA .................................... 79
3.5 Confirmation of genotypes by DNA sequencing analysis .............................................. 84
3.6 Frequency of PDGFRA variant in CML patients treated with IM .................................. 89
3.7 Validation of HRM analysis with DNA sequencing ...................................................... 92
3.8 Genotype frequencies of PDGFRA among IM responsive and IM resistant patients ...... 94
3.9 Association of PDGFRA variants with IM response in CML patients ......................... 96
3.10 Distribution of PDGFRA variant in exons 10 and 12 with the clinical phase ............... 98

CHAPTER 4     DISCUSSIONS

4.1 Epidemiology of CML patients ..................................................................................... 100
4.2 The incidence of PDGFRA variant in CML patients ................................................... 101
4.3 Identification of PDGFRA variant using HRM analysis ............................................. 103
4.4 PDGFRA variant and IM treatment response ............................................................... 105
   4.4.1 PDGFRA exon 10 c.1432 T>C and IM response ................................................... 105
   4.4.2 PDGFRA exon 12 c.1701A>G and IM response .................................................... 107
   4.4.3 PDGFRA exon 14 c.1977 C>G and exon 18 c.2525 A>T and IM response .......... 108
CHAPTER 5  CONCLUSION

5.1  Summary of the study  110
5.2  Study limitations  112
5.3  Future perspective  112

REFERENCES  114

APPENDICES

LIST OF PUBLICATIONS AND PRESENTATION
**LIST OF SYMBOL AND APPENDICES**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>Percent</td>
</tr>
<tr>
<td>ºC</td>
<td>Degree celcius</td>
</tr>
<tr>
<td>&gt;</td>
<td>Change to for SNPs and mutation</td>
</tr>
<tr>
<td>(X^2)</td>
<td>Chi-square</td>
</tr>
<tr>
<td>=</td>
<td>Equal to</td>
</tr>
<tr>
<td>±</td>
<td>Plus minus</td>
</tr>
<tr>
<td>'</td>
<td>Prime</td>
</tr>
<tr>
<td>-</td>
<td>Range</td>
</tr>
<tr>
<td>:</td>
<td>Ratio</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BCR</td>
<td>Breakpoint cluster region</td>
</tr>
<tr>
<td>BCR-ABL</td>
<td>BCR-ABL gene</td>
</tr>
<tr>
<td>BLAST</td>
<td>Basic Local Aligment Search Tool</td>
</tr>
<tr>
<td>BP</td>
<td>Blast phase</td>
</tr>
<tr>
<td>Bp</td>
<td>Base pair</td>
</tr>
<tr>
<td>CCyR</td>
<td>Complete cytogenetic response</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>CP</td>
<td>Chronic phase</td>
</tr>
<tr>
<td>Cq</td>
<td>Quantification cycle</td>
</tr>
<tr>
<td>CyR</td>
<td>Cytogenetic response</td>
</tr>
<tr>
<td>ddH(_2)O</td>
<td>Deionized distilled water</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulphoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>dNTP</td>
<td>Dinucleotide triphosphate</td>
</tr>
<tr>
<td>dsDNA</td>
<td>Double stranded dinucleotide triphosphate</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediamine tetraacetic acid</td>
</tr>
<tr>
<td>G</td>
<td>Gram</td>
</tr>
<tr>
<td>GIST</td>
<td>Gastrointestinal stromal tumour</td>
</tr>
<tr>
<td>HCl</td>
<td>Hydrochloride</td>
</tr>
<tr>
<td>HES</td>
<td>Hypereosinophilic syndrome</td>
</tr>
</tbody>
</table>
HRM  High resolution melting analysis
HPP  Hospital Pulau Pinang
HUSM  Hospital Universiti Sains Malaysia
IM  Imatinib mesylate
KIT  Stem cell growth factor receptor gene
MgCl$_2$  Magnesium chloride
mg/Dl  Milligram per decilitre
min  Minutes
mL  Millilitre
mM  Milimolar
MPN  Myeloproliferative neoplasms
NCBI  National Centre for Biotechnology Information
nm  Nanomolar
NTC  Non template control
P (Pro)  Proline
PCR  Polymerase chain reaction
PDGF  Platelet derived growth factor
$PDGF_{RA}$  Platelet derived growth factor receptor alpha gene
PDGFRA  Platelet derived growth factor receptor alpha protein
PDGFRB  Platelet derived growth factor receptor beta protein
Ph  Philadelphia chromosome
S (Ser)  Serine
Taq  $Thermophilus$ aquaticus
TBE  Tris-Boric Acid-EDTA
TKI  Tyrosine kinase inhibitor
T$_m$  Melting temperature
UK  United Kingdom
USA  United State of America
UV  Ultra violet
V  Volt
WBC  White blood cell
WHO  World Health Organization
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1</td>
<td>Definition of response to tyrosine kinase as first line treatment in LeukemiaNet 2013 recommendation</td>
<td>16</td>
</tr>
<tr>
<td>Table 2.1</td>
<td>List of primers of $PDGFRA$ for HRM analysis</td>
<td>40</td>
</tr>
<tr>
<td>Table 2.2 (a)</td>
<td>Optimized master mix for HRM analysis of exon 10 $PDGFRA$</td>
<td>43</td>
</tr>
<tr>
<td>Table 2.2 (b)</td>
<td>Optimized master mix for HRM analysis of exon 12 $PDGFRA$</td>
<td>43</td>
</tr>
<tr>
<td>Table 2.2 (c)</td>
<td>Optimized master mix for HRM analysis of exon 14 $PDGFRA$</td>
<td>44</td>
</tr>
<tr>
<td>Table 2.2 (d)</td>
<td>Optimized master mix for HRM analysis of exon 18 $PDGFRA$</td>
<td>44</td>
</tr>
<tr>
<td>Table 2.3 (a)</td>
<td>Optimized 3-step cycling HRM protocols for exon 10 $PDGFRA$</td>
<td>47</td>
</tr>
<tr>
<td>Table 2.3 (b)</td>
<td>Optimized 3-step cycling HRM protocols for exon 12 $PDGFRA$</td>
<td>47</td>
</tr>
<tr>
<td>Table 2.3 (c)</td>
<td>Optimized 3-step cycling HRM protocols for exon 14 $PDGFRA$</td>
<td>48</td>
</tr>
<tr>
<td>Table 2.3 (d)</td>
<td>Optimized 3-step cycling HRM protocols for exon 18 $PDGFRA$</td>
<td>48</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>Primer sequences for PCR amplification of $PDGFRA$</td>
<td>52</td>
</tr>
<tr>
<td>Table 2.5 (a)</td>
<td>Optimized master mix composition for exon 10 $PDGFRA$</td>
<td>53</td>
</tr>
<tr>
<td>Table 2.5 (b)</td>
<td>Optimized master mix composition for exon 12 $PDGFRA$</td>
<td>53</td>
</tr>
<tr>
<td>Table 2.5 (c)</td>
<td>Optimized master mix composition for exon 14 $PDGFRA$</td>
<td>54</td>
</tr>
<tr>
<td>Table 2.5 (d)</td>
<td>Optimized master mix composition for exon 18 $PDGFRA$</td>
<td>54</td>
</tr>
</tbody>
</table>
Table 2.6 (a)  Protocol for PCR amplification for exon 10

Table 2.6 (b)  Protocol for PCR amplification for exon 12

Table 2.6 (c)  Protocol for PCR amplification for exon 14

Table 2.6 (d)  Protocol for PCR amplification for exon 18

Table 2.7  Reagent used in preparation of agarose gel electrophoresis

Table 2.8  Formula for sensitivity and specificity of HRM analysis and DNA sequencing

Table 3.1  Summary of sociodemographic and clinical phases of CML patients

Table 3.2  Overall frequency of PDGFRA variant in CML patients (n = 86)

Table 3.3  Summary of combination of PDGFRA variant in IM response and resistance group

Table 3.4  PDGFRA variant obtained by HRM analysis versus DNA sequencing

Table 3.5  Genotype and allele frequencies of PDGFRA variants

Table 3.6  Odd ratios (OR) for the association between targeted PDGFRA variants

Table 3.7  Distribution of PDGFRA variant of exon 10 and exon 12 with CML phases
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>The reciprocal translocation of ABL 1 gene on chromosome 9 into the BCR region on chromosome 22 that result in the formation of Philadelphia (Ph) chromosome</td>
<td>6</td>
</tr>
<tr>
<td>1.2</td>
<td>Chemical structure of Imatinib mesylate</td>
<td>11</td>
</tr>
<tr>
<td>1.3</td>
<td>Schematic diagram on mechanism of action of IM</td>
<td>13</td>
</tr>
<tr>
<td>1.4</td>
<td>Mechanism of resistance against IM</td>
<td>20</td>
</tr>
<tr>
<td>1.5</td>
<td>Schematic diagram of PDGFRA structure</td>
<td>23</td>
</tr>
<tr>
<td>1.6</td>
<td>The normalize melting curve of HRM analysis showing linear decrease of fluorescence as dsDNA denature to ssDNA</td>
<td>26</td>
</tr>
<tr>
<td>1.7</td>
<td>Normalized melt curve graph showing the homozygous wild type (green), homozygous mutant (red) and heterozygous mutant (blue) of HRM analysis</td>
<td>27</td>
</tr>
<tr>
<td>2.1</td>
<td>Flow chart of study</td>
<td>35</td>
</tr>
<tr>
<td>2.2</td>
<td>Thermos Scientific Pikoreal 96 Real-Time PCR machine for High Resolution Melting (HRM) analysis</td>
<td>46</td>
</tr>
<tr>
<td>3.1</td>
<td>2% agarose gel electrophoresis of isolated genomic DNA from blood sample</td>
<td>68</td>
</tr>
<tr>
<td>3.2</td>
<td>The amplification plot of HRM analysis with Cq less than 30</td>
<td>70</td>
</tr>
<tr>
<td>3.3</td>
<td>Normalization plots of HRM analysis for c.1432 T&gt;C in exon 10 of PDGFRA</td>
<td>72</td>
</tr>
<tr>
<td>3.4</td>
<td>Normalization plots of HRM analysis for c.1701 A&gt;C in exon 12 of PDGFRA</td>
<td>74</td>
</tr>
<tr>
<td>3.5</td>
<td>Normalization plots of HRM analysis for c.1977 C&gt;G in exon 14 of PDGFRA</td>
<td>76</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>3.6</td>
<td>Normalization plots of HRM analysis for c.2525 A&gt;T in exon 18 of PDGFRA</td>
<td></td>
</tr>
<tr>
<td>3.7 (a)</td>
<td>2% agarose gel of amplified PCR product of PDGFRA exon 10</td>
<td></td>
</tr>
<tr>
<td>3.7 (b)</td>
<td>2% agarose gel of amplified PCR product of PDGFRA exon 12</td>
<td></td>
</tr>
<tr>
<td>3.7 (c)</td>
<td>2% agarose gel of amplified PCR product of PDGFRA exon 14</td>
<td></td>
</tr>
<tr>
<td>3.7 (d)</td>
<td>2% agarose gel of amplified PCR product of PDGFRA exon 18</td>
<td></td>
</tr>
<tr>
<td>3.8</td>
<td>Electropherogram of DNA sequencing for exon 10 c.1432 T&gt;C</td>
<td></td>
</tr>
<tr>
<td>3.9</td>
<td>Electropherogram of DNA sequencing for exon 12 c.1701 A&gt;C</td>
<td></td>
</tr>
<tr>
<td>3.10</td>
<td>Electropherogram of DNA sequencing for exon 10 c.1977 C&gt;G</td>
<td></td>
</tr>
<tr>
<td>3.11</td>
<td>Electropherogram of DNA sequencing for exon 10 c.2525 A&gt;T</td>
<td></td>
</tr>
<tr>
<td>Appendix</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Appendix A</td>
<td>Ethical approval from Human Research and Ethnic Committee USM (JEPeM)</td>
<td></td>
</tr>
<tr>
<td>Appendix B</td>
<td>Ethical approval from Ministry of Health (NMRR)</td>
<td></td>
</tr>
<tr>
<td>Appendix C</td>
<td>Data collection form</td>
<td></td>
</tr>
<tr>
<td>Appendix D</td>
<td>Patient information and consent form</td>
<td></td>
</tr>
<tr>
<td>Appendix E</td>
<td>Compilation of HRM melt curve profile of <em>PDGFRA</em> exon 10, 12, 14 and 18</td>
<td></td>
</tr>
</tbody>
</table>
APLIKASI ANALISIS PELEBURAN RESOLUSI TINGGI DALAM
PENGESANAN MUTASI GEN PDGFRA DI KALANGAN PESAKIT-
PESAKIT LEUKEMIA MEILOID KRONIK YANG DIRAWAT DENGAN
IMATINIB MESYLATE

ABSTRAK

Pengesanan molekul bagi varian PDGFRA adalah sangat relevan untuk
meramal prognosis dan terapi untuk pesakit leukemia meiloid kronik (CML) yang
dirawat dengan Imatinib mesylate (IM). Walaupun IM telah menunjukkan
keberkesanan dalam rawatan utama CML, namun kemunculan rintangan kepada IM
telah menjadi masalah utama yang membimbangkan. Kemunculan rintangan
terhadap IM boleh disebabkan oleh sama ada mekanisma bersandar BCR-ABL atau
mekanisma tidak bersandar BCR-ABL. Mekanisma tidak bersandar BCR-ABL terdiri
daripada beberapa faktor termasuk perubahan dalam pharmakokinetik IM seperti
penyerapan dan pengedaran metabolism. Walau bagaimanapun, kerintangan terhadap
IM juga boleh berlaku dengan penglibatan tirosina kinase selain daripada BCR-ABL
yang juga terlibat di dalam kerintangan terhadap IM. Sebagai tindak balas kepada
permintaan yang semakin meningkat untuk kaedah yang boleh dipercayai, cepat dan
lebih sensitif, kajian ini menggunakan analisa peleburan resolusi tinggi untuk
menjelaskan mekanisma yang tidak bersandar BCR-ABL yang melibatkan PDGFRA
tirosina kinase pada pesakit CML di Malaysia yang menerima rawatan IM. Sejumlah
86 pesakit CML yang menjalani rawatan IM (43 rintang terhadap IM dan 43 respon
terhadap IM) telah menyertai kajian ini. Menggunakan analisis peleburan resolusi
tinggi, 86 pesakit CML telah disaring untuk PDGFRA ekson 10 (c.1432 T>C), ekson
12 (c.1701 A>G), ekson 14 (c.1977 C>A) and ekson 18 (c.2525 A>T). Sampel yang
mempunyai corak lengkung lebur yang berbeza daripada sampel rujukan telah
diteruskan untuk proses penjusukan DNA bagi mengesahkan genotip. Daripada
analisis data, terdapat dua PDGFRA variasi yang dikenalpasti iaitu PDGFRA ekson
10 dan 12. Profil HRM yang telah ditubuhkan melalui kajian ini menunjukkan 100%
sensitiviti dan spesifisiti jika dibandingkan dengan penjusukan DNA. PDGFRA
ekson 10 menunjukkan faktor risiko yang signifikan untuk pembentukan rintangan
dengan IM (OR 3.797; 95% CI: 1.502 – 9.591; p = 0.005). PDGFRA ekson 12 pula
adalah faktor risiko tidak signifikan (OR 1.597; 95% CI: 0.681 – 3.745; p = 0.281)
untuk kerintangan terhadap IM. Walau bagaimanapun, tiada variasi PDGFRA
dikesan untuk kedua-dua ekson 14 c.1977 C>G dan ekson 18 c.2525 A>T.
Keputusan keseluruhan menunjukkan bahawa PDGFRA mempunyai pengaruh dalam
menentukan kerintangan terhadap IM dalam kalangan pesakit CML dan analisis
selanjutnya perlu dijalankan untuk mengesahkan peranan PDGFRA dalam
mekanisma kerintangan IM pada pesakit CML.
APPLICATION OF HIGH RESOLUTION MELTING (HRM) ANALYSIS IN DETECTION OF PDGFRA GENE MUTATIONS AMONG CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE

ABSTRACT

A molecular detection of PDGFRA variants is highly relevant for prognosis and therapy prediction in chronic myeloid leukemia (CML) patients treated with Imatinib mesylate (IM). Even though IM has shown an excellent efficacy as a frontline treatment in CML, emerging of resistance towards IM in some CML patients has become a major concern. The development of resistance can be either due to BCR-ABL dependent mechanism or BCR-ABL independent mechanism. The BCR-ABL independent mechanisms include factor in pharmacokinetics of IM such as absorption and distribution of metabolism. However, resistance to IM can also due to the involvement of others IM targeted tyrosine kinases that may play a role in the IM resistance. In response to growing demand for reliable, faster and more sensitive methods, the present study used a High resolution melting (HRM) analysis to elucidate the BCR-ABL independent mechanism involving PDGFRA tyrosine kinase, in Malaysian CML patients undergoing IM therapy. A total of 86 CML patients on IM therapy (43 IM resistances and 43 IM responses) were included in this study. Using HRM analysis, 86 CML patients were screened for PDGFRA variants of exon 10 (c.1432 T>C), exon 12 (c.1701 A>G), exon 14 (c.1977 C>A) and exon 18 (c.2525 A>T). The selected samples with showing different melting curve profile from the reference genotype was subjected to DNA sequencing analysis to validate the genotype. From the data analysed, two PDGFRA variants were detected in exons 10
and 12. The established HRM profile has demonstrated 100% sensitivity and specificity when compared to DNA sequencing. *PDGFRA* exon 10 (c.1432 T>C) showed a significant risk factor (OR 3.797; 95% CI: 1.502 – 9.591; p = 0.005) for the development of IM resistance. *PDGFRA* exon 12 (c.1701 A>G) was not a significant risk factor (OR 1.597; 95% CI: 0.681 – 3.745; p = 0.281) for IM resistance. However there was no *PDGFRA* heterogeneity detected for both exon 14 c.1977 C>G and exon 18 c.2525 A>T. The results suggested that *PDGFRA* influenced IM resistance in CML patients and further analysis are warranted to confirm the role of *PDGFRA* in IM resistance mechanism in CML patient.
CHAPTER 1

LITERATURE REVIEW

1.1 Study overview

Leukemia is defined as the uncontrolled proliferation or expansion of haematopoietic cells that do not retain the capacity to differentiate normally to mature white blood cells. In 2010, the incidence of leukemia was reported to be increased over the years from 30,800 cases in year 2000 to 44,790 in year 2009 worldwide and it was estimated that by 2018, 60,300 people diagnosed with leukemia in United States (Panno, 2005; Murphy et al., 2018). In Malaysia population, leukemia was reported to be the sixth most frequent cancer from 2007 to 2011, after lymphoma and cancer of nasopharynx, and it accounted for 4.4% of all types of cancer (Azizah et al., 2016).

According to World Health Organisation (WHO) leukemia is divided into two main classes according to their progression. It can be either acute leukemia or chronic leukemia. In acute leukemia, the abnormal blasts remain very immature and the number of blasts increases rapidly. While for chronic leukemia, the cells are more mature with presence of some blasts cells and will progress slowly and gradually than in acute leukemia.

This leukemia can arise either of the two types of white blood cells – lymphoid cells or myeloid cells. Based on the cells affected, there are four types of leukemia; acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).
Acute lymphocytic leukemia (ALL) is marked by neoplasia of precursor B- or precursor T-lymphoid cells in blood. It was reported to be the most common cancer among children with highest incidence among aged 1 to 10 years. In ALL, the accumulation of leukemic cell in the bone marrow and extramedullary site occur due to abnormal proliferation and differentiation of the leukemic cells which may lead to anemia, splenomegaly, hepatomegaly, lymphadenophaty and other manifestation of organ infiltration (Kebriaei et al., 2002).

Acute myeloid leukemia (AML) is a type of leukemia that affects the myeloid cells. AML grows rapidly which is characterized by accumulation of immature blastic cells that proliferate abundantly with lack of normal differentiation (Mendelsohn et al., 2008).

Chronic lymphoid leukemia (CLL) is reported to be the most common form of leukemia in adults with more than 10,000 people diagnosed every year in the United State with approximately 75% of survival rate (Bozzone, 2009). CLL affects the lymphoid cells which progress slowly over times.

In CML, the myeloid cells undergone uncontrolled expansion of mature and maturing granulocytic cells without loss their capacity to differentiate. The incidence were about 1 to 2 cases per 100,000 adults and classified as the most common chronic myeloproliferative disorder (Jemal et al., 2010). CML commonly affect older patients with a median age of about 65 years and rarely diagnosed in children (Zhang and Rowley, 2011). In Malaysia, the occurrence of CML in 2007 to 2011 was reported as 14.1% of all type of leukemia and 29.9% of myeloid leukemia (Azizah et al., 2016). Even though the incidence rate in Asian countries is lower compared to
Western countries, the occurrence of CML in Asians tends to affect younger population with median age 36 years old (Au et al., 2009).

CML is associated with the presence of the Philadelphia (Ph) chromosome and it was the first cancer that shows a consistent genetic abnormality (Sherbenou and Druker, 2007). The presence of Ph chromosome has become a hallmark in CML identification. The Ph chromosome was first discovered by Nowell and Hungerford in 1960 and later Janet Rowley that characterized the Ph chromosome to be the results of reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;q11).

In early 1980s, with the enhancement of molecular biology has led to the discovery of human homologue of the murine Abelson1 gene (ABL1gene) which located on chromosome 9 was found to be translocated to the chromosome 22 in CML patients. Later in 1984, the breakpoint cluster region (BCR gene) on chromosome 22 was explored (Goldman and Mughal, 2008). The translocation has resulted in a BCR-ABL fusion gene (Figure 1.1). this fusion gene codes for BCR-ABL transcript and fusion protein with a constitutively active tyrosine kinase activity and increased activation of multiple signal transduction pathways (Kurzrock et al., 1988). These, later will leads to a massive production of myeloid cell that induce leukemia. The Ph chromosome has been observed in approximately 95% among CML patients (Faderl et al., 1999).

The presence of well-defined pathogenetic of CML has led to the development of IM which is a tyrosine kinase inhibitor that inhibit both ABL and BCR-ABL protein. Since the BCR-ABL fusion protein is a constitutively activated tyrosine kinase that causes CML, IM has been one of the treatment options in treating newly diagnosed patients or patient who have not respond to previous treatment (Druker et al., 2001).
The clinical use of IM has resulted in significantly improve prognosis and survival rate where 80% to 90% of patients in early chronic phase have shown major cytogenetic responses toward IM (Buchdunger et al., 2001).

In addition to BCR-ABL, IM also inhibits other tyrosine kinases of c-KIT and platelet derived growth factor alpha (PDGFRα). Platelet derived growth factor (PDGF) receptor is belong to the receptor tyrosine kinase family of type III group. The genetic alteration of this receptor was reported mostly in myeloproliferative disorder and solid tumor such as in myelomonocytic leukemia, gastrointestinal stromal tumors (GISTs) and gliomas (Arora and Scholar, 2005; Demoulin and Montano-Almendras, 2012). The discovery that IM also blocks PDGF receptor was a major breakthrough. Where, it have shown to inhibit PDGFRα at the concentration similar to the inhibition concentration for BCR-ABL (Heinrich et al., 2000). In addition, several studies also showed a significant response of IM to the treatment of GIST patients which involved the PDGFRα kinase (Druker, 2004).

However, until today some patients in both CML and GIST has become resistant towards IM therapy. The emergence of resistance has prompted intense research on wider prospects of mechanism involve in IM resistant. Previous studies have showed that PDGFRα exon 10, 12, 14 and 18 were the most common site for PDGFRα mutation that associated with IM treatment response (Holtkamp et al., 2006). Therefore, this present study focused on application of High Resolution Melting (HRM) analysis in detection of PDGFRα variant in exon 10, 12, 14 and 18 and its association with IM resistant in CML patients.

HRM analysis is gaining more demands upon today’s laboratories to generate a great need for rapid and cost-effective analytical methods. This technique was first
introduced in 2002 by a collaboration between academics at the University of Utah (UT, USA) and company Idaho Technology (UT, USA) (Montgomery et al., 2010). The flexibility of HRM analysis has allowed it to be applied in a wide range of disciplines for a variety of applications including gene scanning, genotyping, sequence matching and also in methylation analysis (Erali et al., 2008). Perhaps, this technique would be able to discriminate even small sequence variations of single base substitution in PDGFA gene.
Figure 1.1  The reciprocal translocation of ABL1 gene on chromosome 9 into the BCR region on chromosome 22 that resulted in the formation of Philadelphia (Ph) chromosome (Adapted from (Ali, 2016)).
1.2 Chronic Myeloid Leukemia and clinical phases

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease originating from an abnormal pluripotent bone marrow stem cell. The progression of CML is slow during their early phases (Goldman and Mughal, 2008). The disease is neither preventable nor inherited and the cause for its formation is unknown in majority of the patients (Quintás-Cardama and Cortes, 2006).

CML consists of three phases based on clinical features and laboratory findings: the chronic phase (CP), the accelerated phase (AP) and the blast phase (BP) or blast crisis. Most cases of CML are diagnosed during the CP with a few clinical sign and symptoms that vary among individuals include fatigue, anemia, progressive splenomegaly and leucocytosis. CML patients at this phase usually have mild symptoms and usually asymptomatic. Approximately 90% of patients are diagnosed in the CP (Cortes et al., 2006). According to World Health Organization (WHO), CP is characterized by < 10% blasts in the blood which can last for several years. Without effective treatment, CML can progress to the AP or BP which usually associated with additional chromosomal and molecular alterations (Calabretta and Perrotti, 2004).

In AP, patients may show a sign of 10 to 19% of blasts in peripheral blood, presence of ≥ 20% basophils, persistent thrombocytopenia and increasing spleen size (Baccarani et al., 2013). According to Cortes et al, in 2006, two-third of patients go through the AP before develop into the BP which is the terminal phase of CML. It is characterized by more than 20% of leukemic cells in blood with extramedullary involvement (Kantarjian et al., 1988; Baccarani et al., 2013). At this blast phase,
immature cells proliferate rapidly and progression of disease considerably fast within 5 years of diagnosis.

1.3 Diagnosis of CML

CML is diagnosed by means of haematological testing, cytogenetic analysis and molecular diagnosis. Complete blood count is the first indicator of CML diagnosis. The typical haematologic findings are anemia with haemoglobin level less than 7 gm/dl to 11 gm/dl as well as marked leucocytosis with elevation of total leukocyte count from 100 to 500 x 10^9/L. The peripheral blood smear demonstrated immature white cells of all stages including neutrophils, metamyelocytes, myelocytes, promyelocytes and blast cells. The abnormal results in blood screening are followed with bone marrow aspirate analysis and trephine biopsy. The bone marrow aspirate usually shows a marked myeloid hyperplasia together with markedly increased of myeloid to erythroid precursor (M:E) ratio from 20:1 to 49:1 (Rodgers and Young, 2013).

The cytogenetics analysis is performed by mean of chromosome banding analysis (CBA) of marrow cell metaphases (Shaffer et al., 2013) to detect additional chromosomal abnormalities which determined by the presence of Ph chromosome. If marrow cells cannot be obtained, CBA can be replaced by interphase fluorescence in situ hybridization (I-FISH) using dual colour fusion probes that allow detection of BCR-ABL + nuclei to detect some variant translocation (Testoni et al., 2009).

More recently, molecular diagnostic methods including FISH and quantitative reverse transcription polymerase chain reaction (qRT-PCR) have been introduced
and were reported to be more sensitive than conventional cytogenetic analysis for the
detection of $BCR-ABL$ positive cells. The qRT-PCR analysis identifies the transcript
types of either $e14a2$ or $13a2$ (also known as $b3a2$ and $b2a2$) and rarely recognizes
the transcript of $e19a2$ or $e1a2$ which indicate the $BCR-ABL$ protein weight
(Baccarani et al., 2012).

1.4 Treatment and management

Treatment of the CML in last century was based on radiotherapy, busulfan, and
hydroxyurea (Pavlovsky et al., 2009). Those treatments were able to control the
clinical manifestation of the disease, but rarely of capable to supress the progression
of the disease. Following this, interferon-alpha and allogenic stem cell
transplantation was introduced and showed to induce cytogenetic response among
the patients (Goldman, 2009; Pavlovsky et al., 2009).

Increase understanding on the molecular pathogenesis of CML and discovery of the
Philadelphia chromosome has led to the development of IM; the tyrosine kinase
inhibitor (TKI) that target the $BCR-ABL$ protein (Pavlovsky et al., 2009). Since then,
IM has become a gold standard treatment that results in dramatically improved
clinical management and outcome in CML patients (Manley et al., 2002).

1.5 Imatinib mesylate

Imatinib mesylate also known as Gleevec or formely referred as STI571 (Norvatis,
Switzerland), is a specific inhibitor of tyrosine kinases $BCR-ABL$ and platelet-
derived growth factor (PDGF) and stem cell factor (Savage and Antman, 2002). IM
was designated chemically as 4-[[4-methyl-1-[1piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl] benzamide nethanesulfonate with a molecular formula of C$_{29}$H$_{31}$N$_{7}$O.CH$_{4}$SO$_{3}$ and relative molecular mass of 589.7 (Cohen et al., 2002). IM has been approved by the Food and Drug Administration (FDA) for treatment of CML and gastrointestinal stromal tumors (GISTs) (Savage and Antman, 2002; O'Brien et al., 2003). The initial standard doses of IM for a newly diagnosed Ph+ CML patients is 400 mg daily and 600 mg daily for CML patients in the accelerated and blasts phases (Talpaz et al., 2002; Druker, 2004; Pavlovsky et al., 2009). Figure 1.2 shows the chemical structure of IM.

Administration of IM to CML patients has resulted in marked clinical response. An *in vitro* and *in vivo* study, has shown the ability of IM to inhibit proliferation of cells expressing *BCR-ABL* and have reduced the formation of the *BCR-ABL* positive colonies by 95% (Buchdunger et al., 2001; Savage and Antman, 2002). About 65% to 90% CML patient who have failed interferon-α and 80% to 90% of untreated CML patients have showed to induce complete cytogenetic response (CCyR) from the IM treatment which demonstrated by the complete absence of Ph chromosome in CML cell metaphases (Druker et al., 2001; Kantarjian et al., 2002). IM therapy specifically inhibit proliferating myeloid cell with minimal side effects including neutropenia, thrombocytopenic anemia and non-hematologic adverse effects including nausea, skin rash, peripheral edema and muscle cramps which only can be observed in 10 to 20% of patients (Arora and Scholar, 2005).
Figure 1.2  Chemical structure of IM (Adapted from (Manley et al., 2002)).
1.5.1 Mechanism of action

IM was developed as a specific inhibitor of the BCR-ABL protein tyrosine kinase. IM exhibits potent inhibitory activity against ABL kinase and the chimeric BCR-ABL fusion oncprotein, KIT, and PDGFR (Quek and George, 2010).

At the cellular level, IM binds to the inactive form of ABL kinase and function as a competitive inhibitor of the adenosine triphosphate (ATP) binding site of the BCR-ABL protein. The main purpose of the IM binding is to block the autophosphorylation of the ABL kinase, which responsible for kinase activation and signal transduction (Buchdunger et al., 2002). In BCR-ABL expressing cells, IM has shown to produce three related effects; inhibition of BCR-ABL autophosphorylation, inhibition of proliferation and induction of apoptosis (Druker et al., 1996; Gambacorti-Passerini et al., 1997).

The BCR-ABL protein targets were reported to include members of Ras, Phosphatidylinositol-3 kinase (PI3K)/Akt and Jak/Stat signalling pathway that play a role in regulating cell proliferation and apoptosis. BCR-ABL also act by repealing the cell dependence on external growth factors by up-regulating the production of interleukin-3 as well as altering the cell adhesion properties by expression and activation of the focal adhesion kinase and associated proteins. Therefore, IM prevented the BCR-ABL tyrosine kinase enzyme from phosphorylating subsequent proteins and initiating the signalling cascade (Kantarjian et al., 2006). The schematic diagrams of how IM works as competitive inhibitor of ATP was shown in Figure 1.3.
**Figure 1.3** Schematic diagrams on mechanism of action of IM. (A) Activation of BCR-ABL that led to autophosphorylation of ABL kinase (B) Binding of IM to the BCR-ABL that block the autophosphorylation of ABL kinase thus inhibit intracellular signals (Adapted from (Ali, 2016)).
1.6 IM resistance

The responses toward IM treatment are assessed based on three types of response, which are the haematological response, cytogenetic response and molecular response. These responses were assessed on the third month of continuous IM treatment followed by sixth month, twelfth month and each subsequent three months later. According to LeukemiaNet 2013 recommendation (Table 1.1), IM response groups were divided into three major groups, which are the optimal, warning and failure. The response criteria were mostly based on the molecular response.

However, some CML patients has experience an unsatisfactory therapeutic effects with IM. The main reason is because of the development of resistance to IM. The resistance to IM can be divided into primary resistance and secondary resistance. Where, both groups have led to less favourable prognosis to CML patients.

The primary resistance or also known as intrinsic resistance is defined as having less than complete cytogenetic response within 12 months after IM treatment initiation and/or having more than 1% of BCR-ABL1 transcript when tested with (RT-qPCR) (Baccarani et al., 2013).

While, secondary resistance which known as acquired resistance was characterized by loss of complete haematological response, complete cytogenetic response, loss of major molecular response confirm with two constitutive test to show the presence of BCR-ABL1 transcripts level of more or equal to 1% and may presented with mutations and/or clonal chromosome abnormalities (Baccarani et al., 2013)

Approximately about 33% of CML patients treated with IM do not achieve complete cytogenetic response (CCyR) (Bixby and Talpaz, 2009; Hochhaus et al., 2009).
mechanisms of resistance to IM have been extensively studied and can be divided into two main types which are BCR-ABL dependent and BCR-ABL independent (Figure 1.4).
Table 1.1  Definition of response to tyrosine kinase inhibitor as first line treatment in LeukemiaNet 2013 recommendation.

<table>
<thead>
<tr>
<th>Time</th>
<th>Optimal response</th>
<th>Warning</th>
<th>Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>N/A</td>
<td>High risk</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Major route</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCA/Ph+</td>
<td></td>
</tr>
<tr>
<td>3 months</td>
<td>$BCR-ABL1 \leq 10%$ and/or $Ph+ \leq 35% (PCyR)$</td>
<td>$BCR-ABL1 &gt; 10%$ and/or $Ph+ 36-95%$</td>
<td>No CHR</td>
</tr>
<tr>
<td>6 months</td>
<td>$BCR-ABL1 &lt; 1%$ and/or $Ph+ 0% (CCyR)$</td>
<td>$BCR-ABL1 1-10%$ and/or $Ph+ 1-35%$</td>
<td>$BCR-ABL1 &gt; 10%$ and/or $Ph+ &gt; 35%$</td>
</tr>
<tr>
<td>12 months</td>
<td>$BCR-ABL1 \leq 0.1%$ (MMR)</td>
<td>$BCR-ABL1 0.1-1%$ and/or</td>
<td>$BCR-ABL1 &gt; 1%$ and/or $Ph+ &gt; 0%$</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Then, and at any time</td>
<td>MMR or better CCA/Ph- (-7 or 7q-)</td>
<td>Loss of CHR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Loss of CCyR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Loss of MMR*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mutations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CCA/Ph+</td>
</tr>
</tbody>
</table>

N/A: Not available; MMR: $BCR-ABL1 \leq 0.1\%=\text{MR or better}$; CCA/Ph+: Clonal chromosomal abnormalities in Ph+ cells; CCA/Ph-: Clonal chromosomal abnormalities in Ph- cells; *: in 2 consecutive test of which $BCR-ABL1$ transcript level $\geq 1\%$
1.6.1 *BCR-ABL* dependent

There are two main mechanisms involved under the BCR-ABL dependent which are amplification of *BCR-ABL* gene and point mutation in the tyrosine kinase domain of the *ABL* gene (Gambacorti-Passerini *et al.*, 2003).

The amplification of *BCR-ABL* gene in IM resistant leukemic cells was first described in a LAMA84R cell line generated by culturing cells with increasing IM concentrations where it express about five times more BCR-ABL protein compared to the parent LAMA84 cells. Further analysis using marker chromosome labelled by *BCR-ABL* specific probe confirmed that the overexpression of the protein was because of the amplification of the *BCR-ABL* gene (le Coutre *et al.*, 2000). While, the fluorescence *in situ* hybridization (FISH) of CML blast phase patients following treatment with IM discovered the same finding of *BCR-ABL* amplification (Melo and Chuah, 2007).

As IM was a competitive inhibitor of the ATP binding site of ABL, mutations affecting IM binding were likely to produce non-functioning enzymes. However, later studies showed that IM binds and stabilise ABL in its inactive conformation where no ATP binds to the kinase rather than competing with ATP for binding. Consequently, mutations in the kinase domain of *BCR-ABL* may be able to disrupt IM binding without interfering its enzymatic activity (Tauchi and Ohyashiki, 2004). Investigation of mechanism of IM resistance then has led to the discovery of T315I mutation in the ABL kinase domain of *BCR-ABL* that confers resistant toward IM via blocking IM binding to ABL where has subsequently been found in at least one *BCR-ABL* positive cell (Gorre *et al.*, 2001; Ricci *et al.*, 2002).
1.6.2 *BCR-ABL* independent

*BCR-ABL* independent mechanism mainly involves several factors and can be due to alterations in their pharmacokinetics for example drug efflux/influx and binding of IM in the plasma by α-1 acid glycoprotein. Overexpression of adenosine triphosphate binding cascade (ABC) transporter in the cell of blast phase CML patients has been linked to the development of IM resistance. This ABC transporter is a transmembrane protein that regulates efflux of numerous chemotherapeutic agents (Mahon *et al.*, 2000). Whereas, influx inhibition through human organic cation transporter (hOCT1) was also an important factor that affects regulation intracellular IM and any polymorphism in these transporter have the ability to alter the entry of IM into the cell which may contribute to development of resistance (Crossman *et al.*, 2005; Quintas-Cardama and Cortes, 2009).

When leukemic cells from patients were analysed after initial treatment with IM, only partial inhibition was observed although *BCR-ABL* could completely blocked when exposed to the equivalent plasma IM concentrations (Druker *et al.*, 2001; Gambacorti-Passerini *et al.*, 2002). These can be explained that approximately 95% of IM is bound to the plasma protein which is α-1-acid glycoprotein (AGP) and albumin. The binding of AGP can inhibit the activity of IM (Gambacorti-Passerini *et al.*, 2000; Larghero *et al.*, 2001; Le Coutre *et al.*, 2002). Therefore, IM that present in the plasma could be mostly bound to the AGP and thus biologically inactive.

The resistance that involving *BCR-ABL* independent is not only due to the mechanism mentioned above. Several studies had reported that a significant portion of IM resistance in CML patients could not be associated with *BCR-ABL* fusion gene. Therefore it is presumed that the mechanism of IM resistance in such patients
might be via additional mechanisms involving other IM targeted tyrosine kinases for example PDGFRA which could also affecting the response of IM
Figure 1.4  Mechanisms of resistance against IM. (1) Mutation in the BCR-ABL gene (2) Amplification of BCR-ABL (3) Drug influx/efflux mechanisms (4) Autocrine cytokine secretion (5) Activation of alternative signalling pathway (6) Wnt/β-catenin pathway (7) low intracellular drug availability (Adapted from (La Rosée and Deininger, 2010)).
1.7 Tyrosine kinase

Tyrosine kinases are enzymes that catalyse the transfer of the gamma (γ) phosphate group from adenosine triphosphate to target protein. It plays a role in diverse regulatory processes including the modulation of growth factor signalling, proliferation and differentiation. Tyrosine kinases can be classified into receptor protein kinase and non-receptor protein kinase. There are approximately 60 RTKs that have been identified and further divided into 20 subfamilies (Pawson, 2002).

The receptor tyrosine kinase are activated by ligand binding which then induce dimerization of these receptor resulting in autophosphorylation of their cytoplasmic domain and activation of the tyrosine kinase activity (Paul and Mukhopadhyay, 2004). The most important downstream signalling pathways activated by receptor tyrosine kinase including the Ras/Raf mitogen-activated protein kinase pathway, the phosphoinositol 3’-kinase/AKT pathway, the signal transducer and activator of transcription 3 pathway (JAK/STAT), the protein kinase C pathway and scaffolding protein (Schlessinger, 2000). These intracellular mediators then effects the biological processes including cell growth, migration, differentiation and death (Blume-Jensen and Hunter, 2001).

Even there are multiple levels of regulation of tyrosine kinase, dysregulation may also occur which lead to malignancy through several mechanisms including amplification of receptor tyrosine kinase gene, genetic alterations and autocrine-paracrine stimulation through aberrant growth factor loops (Zwick et al., 2002). In CML, the related tyrosine kinase involve is the ABL gene which classified under non-receptor tyrosine kinase. However in this study we are exploring others tyrosine kinase which is PDGFRA that classified under type III receptor tyrosine kinase, since
the receptor in this class is one of the intriguing receptor tyrosine kinase in terms of evolutionary, functional and clinical considerations (Grassot et al., 2006; Verstraete and Savvides, 2012).

1.7.1 Platelet-derived growth factor receptor alpha (PDGFRA)

Platelet derived growth factor receptor (PDGFR) or also known as CD140A and PDGFR2 is belongs to the class III of tyrosine kinases have shown to play a role in mesenchymal cell migration and proliferation (Jones and Cross, 2004). These growth factors are mitogens for the cells of mesenchymal origin. Two type of PDGFRs have been identified which are alpha type (PDGFRA) and beta type (PDGFRB). These two types of subunit are differently expressed on the cell surface of different cell types.

The full length PDGFRA is encoded by a 6.4 kb transcript generated from a promoter upstream of exon 1 (P1 promoter). It is located at chromosome 4 in the 4q12 and has 23 exons and 1089 amino acid residues (Mosselman et al., 1996). The structure of PDGFRA receptor comprises an extracellular domain with five immunoglobulin (Ig), a juxtamembrane domain inside the cell membrane and two cytoplasmic tyrosine kinase domain (Figure 1.5) (Claesson-Welsh et al., 1989; Matsui et al., 1989). PDGFRA bind to its ligand (PDGF-A, -B, -C and –D) and induce receptor dimerization that lead to autophosphorylation of their cytoplasmic tyrosine residue thus activate inter/intracellular kinase activity, initiating the intracellular signalling (Kawagishi et al., 1995).
Figure 1.5  Schematic diagram of PDGFRA structure (Adapted from (Li et al., 2017).
1.7.2 *PDGFRA* and IM resistance

In addition to *BCR-ABL*, IM is also a potent inhibitor for c-*KIT* and *PDGFRA* in gastrointestinal stromal tumour (GISTs), and also has shown marked response as a treatment in glioblastoma, dermatofibrosarcoma protuberans, malignant peripheral nerve sheet tumour (MPNST) and chronic myelomonocytic leukemia (Buchdunger *et al.*, 2002). Several clinical trials have demonstrated a significant response to IM in advanced GISTs patients and have shown to inhibit the *PDGFRA* tyrosine kinase at the concentration similar to the concentration required for the inhibition of *BCR-ABL* in CML (Heinrich *et al.*, 2003a).

Mutations of *PDGFRA* lead to ligand-independent activation of the receptor. Approximately about 80% of GISTs patients expressed the mutated KIT receptor. However about 8% of the patients had a normal KIT and 5% of the patients demonstrated to have mutation in the PDGFRA receptor (Joensuu, 2006). Since, *PDGFRA* is very similar to the *KIT* and found in close proximity on chromosome 4q12, the mutation of the receptor seen to be related (Spritz *et al.*, 1994).

Most of the *PDGFRA* mutations occur in exons 10, 12, 14, 18 in GISTs and MPNT. The site of mutations may influence response to tyrosine kinase inhibitors such as IM (Holtkamp *et al.*, 2006). Mutation in exon 18 of *PDGFRA* (D842V) has shown to be resistant toward IM therapy which account for about 89.6% of cases in GISTs (Corless *et al.*, 2005). It is suggested that a similar mutational status of *PDGFRA* might also occur in CML patients that causes development of resistance towards IM treatment.